GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » Research & Development

RVL Pharmaceuticals (FRA:O1P) Research & Development : €2.98 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. RVL Pharmaceuticals's Research & Development for the three months ended in Jun. 2023 was €0.51 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was €2.98 Mil.

RVL Pharmaceuticals Research & Development Historical Data

The historical data trend for RVL Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Research & Development Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial 38.41 29.09 11.00 6.13 3.74

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 1.05 0.83 0.59 0.51

RVL Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals  (FRA:O1P) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

RVL Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (FRA:O1P) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » Research & Development
Comparable Companies
SNPX THAR SLRX PHIO PXMD HSTC NVIV IVBT ATNF ENSC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RVLPQ:USA
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
Website
https://www.rvlpharma.com
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

RVL Pharmaceuticals (FRA:O1P) Headlines

No Headlines